Abstract
In this issue of Blood, Meissner and colleagues discover that immune cells from CGD patients that have defective phagocyte oxidases show hyperactive inflammasome activation. These findings implicate that ROS down-regulate rather than enable caspase-1 activation and identify anti–IL-1 strategies as a potential therapy for the disproportionate inflammatory responses associated with CGD.